{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:49:00Z","timestamp":1794606540081,"version":"4.9.1"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118669","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:38:31Z","timestamp":1761323911000},"page":"118669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Neurologic complications of immune checkpoint inhibitors: A comprehensive review"],"prefix":"10.1016","volume":"192","author":[{"given":"Saeed Zivari","family":"Lashkajani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman Sadat","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Taha","family":"Nami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Darzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahla","family":"shokouhfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina Naddaf","family":"faizabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Diansaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komeil","family":"Aghazadeh-Habashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Azimzadeh","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Ghorbani","family":"Vanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118669_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211038735","article-title":"Cancer biology, epidemiology, and treatment in the 21st century: current status and future challenges from a biomedical perspective","volume":"28","author":"Pi\u00f1a-S\u00e1nchez","year":"2021","journal-title":"Cancer Control"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib2","article-title":"Editorial for the special issue \"latest review papers in molecular oncology 2023\"","volume":"25","author":"Stolfi","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"26","key":"10.1016\/j.biopha.2025.118669_bib3","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.12998\/wjcc.v9.i26.7643","article-title":"Combined targeted therapy and immunotherapy for cancer treatment","volume":"9","author":"Guo","year":"2021","journal-title":"World J. Clin. Cases"},{"issue":"9","key":"10.1016\/j.biopha.2025.118669_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing cancer treatment: recent advances in immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118669_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118669_bib6","article-title":"Clinical cancer immunotherapy: current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061319","article-title":"Neurological Immune-Related adverse events induced by immune checkpoint inhibitors","volume":"12","author":"Stavropoulou De Lorenzo","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2025.118669_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14740\/wjon1575","article-title":"Neurological adverse effects of immune checkpoint inhibitors and chimeric antigen receptor T-Cell therapy","volume":"14","author":"Khalid","year":"2023","journal-title":"World J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12957-023-03212-5","article-title":"Neoadjuvant PD-1\/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis","volume":"21","author":"Huang","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621639","article-title":"Treatment-Related serious adverse events of immune checkpoint inhibitors in clinical trials: a systematic review","volume":"11","author":"Ouyang","year":"2021","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory t cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.biopha.2025.118669_bib14","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118669_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17512433.2023.2211262","article-title":"Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management","volume":"16","author":"Ruggiero","year":"2023","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2025.118669_bib17","article-title":"A review of neurotoxicities associated with immunotherapy and a framework for evaluation","volume":"3","author":"Burton","year":"2021","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.biopha.2025.118669_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin","year":"2024","journal-title":"Front Neurol."},{"key":"10.1016\/j.biopha.2025.118669_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643291","article-title":"Immunotherapy goes local: the central role of lymph nodes in driving tumor infiltration and efficacy","volume":"12","author":"van Pul","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010130","article-title":"Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in Neuro-Oncology practice: case series","volume":"12","author":"Marco","year":"2022","journal-title":"J. Clin. Med"},{"issue":"21","key":"10.1016\/j.biopha.2025.118669_bib21","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1097\/CM9.0000000000000972","article-title":"Type 1 diabetes induced by immune checkpoint inhibitors","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin. Med J. (Engl. )"},{"key":"10.1016\/j.biopha.2025.118669_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint Inhibitor-Associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118669_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042093","article-title":"Immune checkpoint Inhibitor-Induced diabetes mellitus: potential role of t cells in the underlying mechanism","volume":"22","author":"Mourad","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12943-023-01845-4","article-title":"Beyond the anti-PD-1\/PD-L1 era: promising role of the BTLA\/HVEM axis as a future target for cancer immunotherapy","volume":"22","author":"Sordo-Bahamonde","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118669_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR t Cell-Associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118669_bib26","article-title":"657\u2005Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma","volume":"8","author":"Saberian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41598-018-36878-z","article-title":"5-Fluorouracil induces enteric neuron death and glial activation during intestinal mucositis via a S100B-RAGE-NF\u03baB-Dependent pathway","volume":"9","author":"Costa","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2025.118669_bib28","doi-asserted-by":"crossref","first-page":"9373","DOI":"10.1002\/cam4.5695","article-title":"Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity","volume":"12","author":"M\u00f6hn","year":"2023","journal-title":"Cancer Med"},{"issue":"13","key":"10.1016\/j.biopha.2025.118669_bib29","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2025.118669_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to Anti-CD19 CAR-T cell therapy for Non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118669_bib31","article-title":"Abstract 5390: high serum interleukin 6 level associates with early death after initiation of treatment with PD-1 inhibitor in advanced NSCLC","author":"Oya","year":"2020","journal-title":"Clin. Res. (Exclud. Clin. Trials)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ejendo\/lvae081","article-title":"HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis","volume":"191","author":"Ono","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118669_bib33","article-title":"Association of human leukocyte antigen (HLA) status with immune checkpoint inhibitor (ICI) pneumonitis in patients with non-small cell lung cancer (NSCLC)","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib34","article-title":"HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker","volume":"14","author":"Amrane","year":"2023","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168988","article-title":"Gene coexpression networks reveal a broad role for lncRNAs in inflammatory bowel disease","volume":"9","author":"Johnson","year":"2024","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/j.biopha.2025.118669_bib36","doi-asserted-by":"crossref","first-page":"e2472","DOI":"10.1212\/WNL.0000000000207632","article-title":"Incidence and outcome of neurologic Immune-Related adverse events associated with immune checkpoint inhibitors in patients with melanoma","volume":"101","author":"Pepys","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2025.118669_bib37","article-title":"NCMP-15. Immune checkpoint inhibitor encephalitis: a retrospective cohort study","author":"Clarke","year":"2021","journal-title":"NeuroOncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118669_bib38","doi-asserted-by":"crossref","first-page":"10509","DOI":"10.3390\/curroncol30120766","article-title":"Exploring a rarity: incidence of and therapeutic approaches for neurological complications and hypophysitis in cancer patients on immune checkpoint Inhibitors-A Single-Center study","volume":"30","author":"Amylidi","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib39","article-title":"NCMP-07. Adverse neurologic complications following immune checkpoint inhibitors for treatment of melanoma: comparative analysis of PD-1 inhibitor monotherapy to combination therapy with CTLA-4 inhibitors","author":"Das","year":"2024","journal-title":"NeuroOncol."},{"issue":"24","key":"10.1016\/j.biopha.2025.118669_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12247564","article-title":"Incidence and timing of Immune-Related adverse events in Immune-Checkpoint Inhibitor-Treated patients: a retrospective observational study","volume":"12","author":"Masaki","year":"2023","journal-title":"J. Clin. Med"},{"issue":"12","key":"10.1016\/j.biopha.2025.118669_bib41","first-page":"7563","article-title":"Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience","volume":"29","author":"Taliansky","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.biopha.2025.118669_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e13541","article-title":"Implementation and impact of a novel multidisciplinary immune-related adverse events tumor board for patients receiving immune checkpoint inhibitor therapy","volume":"39","author":"Boruah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2664","article-title":"Increased incidence of immune-mediated myocarditis in advanced skin malignancies treated with immune checkpoint inhibitors in the COVID-19 era","author":"Gradone","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e14151","article-title":"Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)","author":"Thapa","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2188719","article-title":"Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations","volume":"12","author":"Park","year":"2023","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/jayao.2021.0180","article-title":"Immune-Related toxicity among adolescent and young adult with melanoma as compared with the elderly","volume":"11","author":"Darwin","year":"2022","journal-title":"J. Adolesc. Young.. Adult Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib47","article-title":"Abstract 5200: the incidence and risk factors of hyperprogressive disease(HPD) in non-small cell lung cancer(NSCLC) treated with immune checkpoint inhibitors(ICI)","author":"Kim","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118669_bib48","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-2144","article-title":"Abstract 2144: proteomic study reveals predictive biomarkers of immune-related adverse events in melanoma","author":"Wilmot","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3461","article-title":"Immune-Related adverse events after immune checkpoint inhibitors for melanoma among older adults","volume":"5","author":"Schonfeld","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.biopha.2025.118669_bib50","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1007\/s00432-023-04582-9","article-title":"Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases","volume":"149","author":"Pizuorno Machado","year":"2023","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10067-023-06808-0","article-title":"Overexpression of synoviolin and miR-125a-5p, miR-19b-3p in peripheral blood of rheumatoid arthritis patients after treatment with conventional DMARDs and methylprednisolone","volume":"43","author":"Karamali","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.biopha.2025.118669_bib52","doi-asserted-by":"crossref","first-page":"w20377","DOI":"10.4414\/smw.2020.20377","article-title":"Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature","volume":"150","author":"Stuby","year":"2020","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3892\/mco.2022.2553","article-title":"Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: a case report and literature review of aseptic meningitis as an immune-related adverse event","volume":"17","author":"Inui","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib54","doi-asserted-by":"crossref","DOI":"10.17340\/jkna.2024.0009","article-title":"Atezolizumab induced optic neuritis and aseptic meningitis","author":"Jeong","year":"2024","journal-title":"J. Korean Neurol. Assoc."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib55","article-title":"Posterior reversible encephalopathy syndrome following chemotherapy and immune checkpoint inhibitor combination in a patient with Small-Cell lung cancer","volume":"12","author":"Evin","year":"2022","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.biopha.2025.118669_bib56","article-title":"Immune checkpoint Inhibitor-Induced cerebral pseudoprogression: patterns and categorization","volume":"12","author":"Urban","year":"2021","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib57","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/practneurol-2019-002464","article-title":"Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy","volume":"20","author":"Lyons","year":"2020","journal-title":"Pr. Neurol."},{"key":"10.1016\/j.biopha.2025.118669_bib58","article-title":"Immune checkpoint inhibitor induced autoimmune encephalitis in a patient with metastatic melanoma","author":"Sudhekar","year":"2020","journal-title":"Case Rep. Intern. Med."},{"key":"10.1016\/j.biopha.2025.118669_bib59","doi-asserted-by":"crossref","DOI":"10.2482\/haigan.60.991","article-title":"Acute demyelinating polyneuropathy occurring four days after nivolumab administration in a patient with lung adenocarcinoma","author":"Ohira","year":"2020","journal-title":"Haigan"},{"issue":"5","key":"10.1016\/j.biopha.2025.118669_bib60","first-page":"605","article-title":"[Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events]","volume":"76","author":"Suzuki","year":"2024","journal-title":"Brain Nerve"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib61","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s00415-023-11625-1","article-title":"Peripheral nervous system adverse events associated with immune checkpoint inhibitors","volume":"270","author":"Rossi","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12883-023-03177-8","article-title":"Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report","volume":"23","author":"Park","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.biopha.2025.118669_bib63","doi-asserted-by":"crossref","DOI":"10.33696\/Neurol.6.112","article-title":"Drug-Induced peripheral neuropathy: focus on newer offending agents","author":"Salem","year":"2025","journal-title":"J. Exp. Neurol."},{"key":"10.1016\/j.biopha.2025.118669_bib64","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint Inhibitor-Induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118669_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232920","article-title":"Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease","volume":"13","author":"Leaver","year":"2020","journal-title":"BMJ Case Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib66","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1159\/000510740","article-title":"Immune checkpoint Inhibitor-Induced polymyositis and myasthenia gravis with fatal outcome","volume":"13","author":"Giglio","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.578010","article-title":"Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: a case report","volume":"374","author":"Wako","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118669_bib68","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CJI.0000000000000364","article-title":"Immune checkpoint Inhibitor-related Guillain-Barr\u00e9 syndrome: a case series and review of the literature","volume":"44","author":"Janssen","year":"2021","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib69","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00415-021-10404-0","article-title":"Guillain-Barr\u00e9 syndrome in patients treated with immune checkpoint inhibitors","volume":"268","author":"Fan","year":"2021","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118669_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14080764","article-title":"Unravelling the acute, chronic and Steroid-Refractory management of High-Grade neurological Immune-Related adverse events: a call to action","volume":"14","author":"Malvaso","year":"2024","journal-title":"Brain Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118669_bib71","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1007\/s00415-023-11667-5","article-title":"Dysautonomia associated with immune checkpoint inhibitors","volume":"270","author":"Tezuka","year":"2023","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118669_bib72","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/14712598.2021.1897101","article-title":"A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies","volume":"21","author":"Salim","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118669_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12050088","article-title":"Elevated IL-6 and tumor necrosis Factor-\u03b1 in immune checkpoint inhibitor myocarditis","volume":"12","author":"Ali","year":"2024","journal-title":"Diseases"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib74","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-Interleukin-6 and janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.biopha.2025.118669_bib75","article-title":"Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors","volume":"11","author":"Nakahara","year":"2023","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118669_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1278761","article-title":"Case report: limbic encephalitis following treatment with durvalumab for small-cell lung cancer","volume":"14","author":"Moss","year":"2023","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.70160","article-title":"Pembrolizumab-Induced Anti-Yo-Antibody-Positive cerebellitis: a case report","volume":"13","author":"Yamano","year":"2025","journal-title":"Respirol. Case Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib78","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omae058","article-title":"Cerebral clues: serum neurofilament light chain (sNfL) as a novel biomarker for immune check point inhibitor (ICI) mediated seronegative encephalitis","volume":"2024","author":"Zahid","year":"2024","journal-title":"Oxf. Med Case Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib80","article-title":"Boiled sausage sign: a novel MRI marker for identifying subacute secondary hydrocephalus in the elderly","volume":"17","author":"Yokosaki","year":"2025","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.biopha.2025.118669_bib81","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200287","article-title":"Opsoclonus-Ataxia syndrome in a patient with Small-Cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Farina","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib82","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200218","article-title":"Immune checkpoint Inhibitor-Associated Kelch-Like Protein-11 IgG brainstem encephalitis","volume":"11","author":"Aboseif","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib83","article-title":"Diagnosis and differential diagnosis of neurological adverse events during immune checkpoint inhibitor therapy","volume":"2020","author":"M\u00f6hn","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib84","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.637185","article-title":"Case report: pseudomeningeosis and demyelinating Metastasis-Like lesions from checkpoint inhibitor therapy in malignant melanoma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118669_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001145","article-title":"On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19","volume":"8","author":"Gambichler","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118669_bib86","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/ph17040501","article-title":"Neurological adverse events related to immune checkpoint inhibitors: a practical review","volume":"17","author":"Zammit","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5493\/wjem.v11.i6.79","article-title":"Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"11","author":"Li","year":"2021","journal-title":"World J. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118669_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420932797","article-title":"Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors","volume":"13","author":"Vogrig","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.biopha.2025.118669_bib89","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fneur.2021.642800","article-title":"Paraneoplastic neurological syndromes and beyond emerging with the introduction of immune checkpoint inhibitor cancer immunotherapy","volume":"12","author":"Valencia-Sanchez","year":"2021","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118669_bib90","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2169\/internalmedicine.5629-20","article-title":"Paraneoplastic sensory polyneuropathy related to Anti-PD-L1-including anticancer treatment in a patient with lung cancer","volume":"60","author":"Morimoto","year":"2021","journal-title":"Intern. Med."},{"key":"10.1016\/j.biopha.2025.118669_bib91","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2023.1108116","article-title":"Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events","volume":"14","author":"M\u00fcller-Jensen","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118669_bib92","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2025.118669_bib93","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1351739","article-title":"Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice","volume":"15","author":"von Itzstein","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib94","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118669_bib95","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fneur.2022.936141","article-title":"The role of neurologists in the era of cancer immunotherapy: focus on CAR T-cell therapy and immune checkpoint inhibitors","volume":"13","author":"Pensato","year":"2022","journal-title":"Front. Neurol."},{"issue":"16","key":"10.1016\/j.biopha.2025.118669_bib96","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.7150\/jca.87335","article-title":"The safety of immunosuppressants used in the treatment of Immune-Related adverse events due to immune checkpoint inhibitors: a systematic review","volume":"14","author":"Machado","year":"2023","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib97","first-page":"291","article-title":"Neurological immune-related adverse events associated with immune checkpoint inhibitors: a review of the literature","volume":"16","author":"Fan","year":"2020","journal-title":"AsiaPac. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib98","article-title":"Navigating neurologic adverse events in immune checkpoint inhibitor therapy: challenges and strategies","volume":"3","author":"Aldemir Atmaca","year":"2024","journal-title":"Eurasia J. Med. Adv."},{"key":"10.1016\/j.biopha.2025.118669_bib99","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fneur.2021.655283","article-title":"Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab","volume":"12","author":"Charabi","year":"2021","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118669_bib100","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/brainsci14080764","article-title":"Unravelling the acute, chronic and Steroid-Refractory management of High-Grade neurological Immune-Related adverse events: a call to action","volume":"14","author":"Malvaso","year":"2024","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib101","article-title":"Guillain-Barr\u00e9 Syndrome-Like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases","volume":"2021","author":"Li","year":"2021","journal-title":"BioMed. Res. Int."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib102","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3988\/jcn.2020.16.3.497","article-title":"Pembrolizumab-Induced myasthenic crisis with HyperCKemia in a patient with thymoma","volume":"16","author":"Shin","year":"2020","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.biopha.2025.118669_bib103","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fneur.2022.858628","article-title":"Association between clinical factors and result of immune checkpoint inhibitor related myasthenia gravis: a single center experience and systematic review","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118669_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003585","article-title":"Humoral and cellular correlates of a novel immune-related adverse event and its treatment","volume":"9","author":"Gonugunta","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2025.118669_bib105","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint Inhibitor\u2013Induced myocarditis with Myositis\/Myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"issue":"20","key":"10.1016\/j.biopha.2025.118669_bib106","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.3390\/ijms252010919","article-title":"Balancing tumor immunotherapy and Immune-Related adverse events: unveiling the key regulators","volume":"25","author":"Huang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118669_bib107","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/cancers15092538","article-title":"Steroid-Refractory Immune-Related adverse events induced by checkpoint inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers"},{"issue":"4748","key":"10.1016\/j.biopha.2025.118669_bib108","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20377","article-title":"Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature","volume":"150","author":"Stuby","year":"2020","journal-title":"Swiss Med. Wkly."},{"issue":"4","key":"10.1016\/j.biopha.2025.118669_bib109","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2022.2057223","article-title":"Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev. Neurother."},{"issue":"5","key":"10.1016\/j.biopha.2025.118669_bib110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ane.13291","article-title":"Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis","volume":"142","author":"Nepal","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.biopha.2025.118669_bib111","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR t therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib113","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1159\/000529110","article-title":"Adverse reactions associated with intravenous immunoglobulin administration in the treatment of neurological disorders: a systematic review","volume":"184","author":"Jiang","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.biopha.2025.118669_bib114","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after Immune-Related adverse events in patients with cancer: a systemic review and Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118669_bib115","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1093\/oncolo\/oyae134","article-title":"Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118669_bib116","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fonc.2024.1475502","article-title":"Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis","volume":"14","author":"Cao","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118669_bib117","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fonc.2024.1403658","article-title":"Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis","volume":"14","author":"Eldani","year":"2024","journal-title":"Front. Oncol."},{"issue":"36","key":"10.1016\/j.biopha.2025.118669_bib118","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030236","article-title":"A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: review of literature","volume":"101","author":"Moon","year":"2022","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.biopha.2025.118669_bib119","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11912-022-01241-z","article-title":"Immune checkpoint inhibitor rechallenge and resumption: a systematic review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib120","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.37349\/etat.2024.00275","article-title":"Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer","volume":"5","author":"Musaelyan","year":"2024","journal-title":"Explor. Target. AntiTumor Ther."},{"key":"10.1016\/j.biopha.2025.118669_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120089","article-title":"CNS and PNS manifestation in immune checkpoint inhibitors: a systematic review","volume":"432","author":"Khan","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.biopha.2025.118669_bib122","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin","year":"2024","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib123","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s00415-024-12252-0","article-title":"Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors","volume":"271","author":"Vilaseca","year":"2024","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118669_bib124","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib125","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118669_bib126","article-title":"Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors","volume":"10","author":"Farina","year":"2023","journal-title":"Neurol. Neuroimmunol. amp Neuroinflamm."},{"issue":"9","key":"10.1016\/j.biopha.2025.118669_bib127","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/14712598.2021.1897101","article-title":"A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies","volume":"21","author":"Salim","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib128","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol. Neuroimmunol. amp Neuroinflamm."},{"issue":"11","key":"10.1016\/j.biopha.2025.118669_bib129","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11910-023-01306-x","article-title":"Immune checkpoint inhibitors in patients with Pre-existing neurologic autoimmune disorders","volume":"23","author":"Aoun","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.33696\/Neurol.5.095","article-title":"Atezolizumab induced neurotoxicity: a systematic review","volume":"5","author":"Salem","year":"2024","journal-title":"J. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118669_bib131","article-title":"Clinical course of neurologic adverse events associated with immune checkpoint inhibitors","volume":"11","author":"Rossi","year":"2024","journal-title":"Neurol. Neuroimmunol. amp Neuroinflamm."},{"issue":"8","key":"10.1016\/j.biopha.2025.118669_bib132","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib133","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10072-021-05561-z","article-title":"Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience","volume":"43","author":"Diamanti","year":"2022","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011168","article-title":"Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment","volume":"13","author":"Candido","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11764-023-01507-w","article-title":"Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review","volume":"19","author":"G\u00fcven","year":"2025","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.biopha.2025.118669_bib136","unstructured":"Al-Lahham S.A.\u017da.T. Neurologic Complications of Immune Checkpoint Inhibitors. Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 2022."},{"key":"10.1016\/j.biopha.2025.118669_bib137","unstructured":"Zekeridou C.Z.A. Neurological complications of immune checkpoint inhibitor cancer immunotherapy. May 15, 2021."},{"key":"10.1016\/j.biopha.2025.118669_bib138","doi-asserted-by":"crossref","unstructured":"Antonio Farina C.B., Mad-H\u00e9l\u00e9nie Elsensohn, Alberto Picca Sergio Mu\u00f1iz-Castrillo, Alberto Vogrig, Macarena Villagr\u00e1n-Garc\u00eda, Nicol\u00e1s Lundahl Ciano-Petersen, Luca Massacesi, Baptiste Hervier, Sarah Gu\u00e9gan, Nora Kramkimel, Yann Vano, Joe Elie Salem, Yves Allenbach, Thierry Maisonobe, Souad Assaad, Aur\u00e9lien Maureille, Perrine Devic, Nicolas Weiss, Antoine Pegat, Delphine Maucort-Boulch, Damien Ricard, J\u00e9r\u00f4me Honnorat, Dimitri Psimaras, Bastien Joubert. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. 2023 May 27.","DOI":"10.1093\/braincomms\/fcad169"},{"key":"10.1016\/j.biopha.2025.118669_bib139","doi-asserted-by":"crossref","unstructured":"Patrick Roth S.W., Antonia M.S.M\u00fcller, Reinhard Dummer, Maximilian J.Mair, Dorothee Gramatzki, Emilie Le. Rhun, Markus G.Manz, Michael Weller, Matthias Preusser. Neurological complications of cancer immunotherapy. 2021 Mar 23.","DOI":"10.1016\/j.ctrv.2021.102189"},{"key":"10.1016\/j.biopha.2025.118669_bib140","unstructured":"Alsalem A.N.S., Leslie A.; Briemberg, Hannah R.; Aaroe, Ashley E.; Harrison, Rebecca A. Neurologic Complications of Cancer Immunotherapy. 2023-06-19."},{"key":"10.1016\/j.biopha.2025.118669_bib141","doi-asserted-by":"crossref","unstructured":"I\u00f1igo Les M.M., In\u00e9s P\u00e9rez-Francisco, Mar\u00eda Cabero, Luc\u00eda Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, I\u00f1aki Elejalde, Grazyna Kochan, David Escors. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. 2023 Mar 6.","DOI":"10.3390\/cancers15051629"},{"key":"10.1016\/j.biopha.2025.118669_bib142","article-title":"Progress and challenges of predictive biomarkers for immune checkpoint blockade","volume":"11","author":"Yanna Lei","year":"2021"},{"key":"10.1016\/j.biopha.2025.118669_bib143","doi-asserted-by":"crossref","unstructured":"Ana Carde\u00f1a-Guti\u00e9rrez M.L.B. Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences. 2022 Jun 14.","DOI":"10.3389\/fmed.2022.908752"},{"key":"10.1016\/j.biopha.2025.118669_bib144","doi-asserted-by":"crossref","unstructured":"Ying Zhang X.Z., Weiling Li,Yunyi Du, Wenqing Hu, Jun Zhao. Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. 2022 Dec 31.","DOI":"10.1080\/21645515.2021.2018894"},{"key":"10.1016\/j.biopha.2025.118669_bib145","doi-asserted-by":"crossref","unstructured":"Nikita Das R.D., David C.Kaelber, Michael Kelly, Peter Xie, Deven Reddy. Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma. 2025 Feb 7.","DOI":"10.1093\/noajnl\/vdaf030"},{"key":"10.1016\/j.biopha.2025.118669_bib146","doi-asserted-by":"crossref","unstructured":"A. Farina MV-G, B. Joubert. Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review. 2024 Sep 21.","DOI":"10.1016\/j.neurol.2024.08.007"},{"key":"10.1016\/j.biopha.2025.118669_bib147","doi-asserted-by":"crossref","unstructured":"An-Jie Guo Q.-Y.D., Pan Dong, Lian Zhou, Lei Shi Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors. 2024 Aug 24.","DOI":"10.5306\/wjco.v15.i8.1002"},{"key":"10.1016\/j.biopha.2025.118669_bib148","doi-asserted-by":"crossref","unstructured":"Alberto Vogrig M.D., Irene Florean, Giulia Cellante, Rossana Domenis, Donatella Iacono, Giacomo Pelizzari, Simone Rossi, Valentina Damato, Martina Fabris, Mariarosaria Valente. Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota. 2025 Mar 13.","DOI":"10.3389\/fimmu.2025.1548897"},{"key":"10.1016\/j.biopha.2025.118669_bib149","doi-asserted-by":"crossref","unstructured":"Antonio Farina M.V.-G., Alberto Vogrig, Anastasia Zekeridou, Sergio Mu\u00f1iz-Castrillo, Roser Velasco, Amanda C.Guidon, Bastien Joubert, J\u00e9r\u00f4me Honnorat Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. 2024 Jan.","DOI":"10.1016\/S1474-4422(23)00369-1"},{"key":"10.1016\/j.biopha.2025.118669_bib150","doi-asserted-by":"crossref","unstructured":"S\u00e9bastien Lopes L.P., Thibault Bahougne, Philippe Barth\u00e9l\u00e9my, Romain Guitton, Kevin Didier, Lionnel Geoffrois, Florence Granel-Brocard, Bertrand Mennecier, C\u00e9line Mascaux, St\u00e9phane Kremer, Nicolas Collongues. Central nervous system complications of immune checkpoint inhibitors: A comprehensive review. 2025 Feb.","DOI":"10.1016\/j.critrevonc.2024.104595"},{"key":"10.1016\/j.biopha.2025.118669_bib151","doi-asserted-by":"crossref","unstructured":"Farhan Khalid R.G., Rajvi Gor, Dairya Gor, Vinit Singh, Hussam Eltoukhy. Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy. 2023 Apr.","DOI":"10.14740\/wjon1575"},{"key":"10.1016\/j.biopha.2025.118669_bib152","unstructured":"\u00d6zkan A.L.A.N.Y.E.A., Buket B.A.Y.R.A.M.K.U.V.V.E.T., Arda D.U.M.A.N., Mustafa Cem B.\u00dc.L.B.\u00dc.L., O\u011fuz \u00c7.E.L.E.B.\u0130.,, Murat Serhat A.Y.G.\u00dc.N.B.K., Sinem A.K.B.A.\u015e., \u015eahin L.A.\u00c7.\u0130.N., Piraye O.F.L.A.Z.E.R., Fatih S.E.L.\u00c7.U.K.B.\u0130.R.\u0130.C.\u0130.K., MANDEL N.M. Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach. 2024."},{"key":"10.1016\/j.biopha.2025.118669_bib153","doi-asserted-by":"crossref","unstructured":"Avi Fellner C.M., Michal Lotem, Felix Bokstein, Alisa Taliansky, Shai Rosenberg, Deborah T. Blumenthal, Jacob Mandel, Suzana Fichman, Elena Kogan, Israel Steiner, Tali Siegal, Alexander Lossos, Shlomit Yust-Katz. Neurologic complications of immune checkpoint inhibitors. 2018.","DOI":"10.1007\/s11060-018-2752-5"},{"key":"10.1016\/j.biopha.2025.118669_bib154","unstructured":"Alexandra M. Haugh J.C.P., Douglas B.Johnson Neurologic complications of immune checkpoint inhibitors. 2020."},{"key":"10.1016\/j.biopha.2025.118669_bib155","doi-asserted-by":"crossref","unstructured":"Amanda C.Guidon L.B.B., Bart K.Chwalisz, James Hillis, Teilo H.Schaller, Anthony A.Amato, Allison Betof Warner, Priscilla K.Brastianos, Tracey A.Cho, Stacey L.Clardy, Justine V.Cohen, Jorg Dietrich, Michael Dougan, Christopher T.Doughty, Divyanshu Dubey, Jeffrey M.Gelfand, Jeffrey T.Guptill, Douglas B.Johnson, Vern C.Juel, Robert Kadish, Noah Kolb, Nicole R.Le.Boeuf, Jenny Linnoila, Andrew L.Mammen, Maria Martinez-Lage, Meghan J.Mooradian, Jarushka Naidoo, Tomas G.Neilan, David A.Reardon, Krista M.Rubin, Bianca D.Santomasso, Ryan J.Sullivan, Nancy Wang, Karin Woodman, Leyre Zubiri, William C.Louv, Kerry L.Reynolds Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. 2021 Jul.","DOI":"10.1136\/jitc-2021-002890"},{"key":"10.1016\/j.biopha.2025.118669_bib156","doi-asserted-by":"crossref","unstructured":"Brito M.Hd Neurologic adverse events of cancer immunotherapy. 2022.","DOI":"10.1590\/0004-282x-anp-2022-s116"},{"key":"10.1016\/j.biopha.2025.118669_bib157","doi-asserted-by":"crossref","unstructured":"Martin H.Cherk D.P.N., Thomas W.Barber, Paul Beech, Andrew Haydon, Kenneth S.Yap 18 F-FDG PET\/CT features of immune-related adverse events and pitfalls following immunotherapy. 2022.","DOI":"10.1111\/1754-9485.13390"},{"key":"10.1016\/j.biopha.2025.118669_bib158","doi-asserted-by":"crossref","unstructured":"William C Kreisl M.-J.K., Jennifer M. Coughlin, Ioline D. Henter, David R. Owen, Robert B. Innis. PET Imaging of Neuroinflammation in Neurological Disorders. 2020 Nov.","DOI":"10.1016\/S1474-4422(20)30346-X"},{"key":"10.1016\/j.biopha.2025.118669_bib159","doi-asserted-by":"crossref","unstructured":"Cymon N Kersch P.A., Bronwyn E. Hamilton, Ramon F. Barajas Jr. MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From the AJR Special Series on Inflammation. 2022 Apr.","DOI":"10.2214\/AJR.21.26159"},{"key":"10.1016\/j.biopha.2025.118669_bib160","doi-asserted-by":"crossref","unstructured":"Poorva Jain A.M.C., Mackenzie L. Carlson, Isaac M. Jackson, Anoushka Rao, Michelle L. James Neuroinflammation PET Imaging: Current Opinion and Future Directions. 2020.","DOI":"10.2967\/jnumed.119.229443"},{"key":"10.1016\/j.biopha.2025.118669_bib161","unstructured":"Zhijie Xu X.W., Shuangshuang Zeng, Xinxin Ren, Yuanliang Yan, Zhicheng Gong Applying artificial intelligence for cancer immunotherapy. 2021."},{"key":"10.1016\/j.biopha.2025.118669_bib162","unstructured":"Aloba T.OacO.. Revolutionizing Cancer Immunotherapy: Artificial Intelligence Accelerates Personalized Treatments and Optimizes Patient Outcome. Januaray 2025."},{"key":"10.1016\/j.biopha.2025.118669_bib163","doi-asserted-by":"crossref","unstructured":"Samareh Younesian A.-M.Y., Majid Momeny, Seyed H. Ghaffari, Davood Bashash. The DNA Methylation in Neurological Diseases. 2022.","DOI":"10.3390\/cells11213439"},{"key":"10.1016\/j.biopha.2025.118669_bib164","unstructured":"Tian-Gen Chang Y.C., Hannah J. Sfreddo, Saugato Rahman Dhruba, Se-Hoon Lee, Cristina Valero, Seong-Keun Yoo, Diego Chowell, Luc G.T. Morris, Eytan Ruppin. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features."},{"key":"10.1016\/j.biopha.2025.118669_bib165","unstructured":"Seong-Keun Yoo C.W.F., Byuri Angela Cho, Bailey G. Fitzgerald, Catherine Han, Elizabeth S. Koh, Abhinav Pandey, Hannah Sfreddo, Fionnuala Crowley, Michelle Rudshteyn Korostin, Neha Debnath, Yan Leyfman, Cristina Valero, Mark Lee, Joris L. Vos, Andrew Sangho Lee, Karena Zhao, Stanley Lam, Ezekiel Olumuyide, Fengshen Kuo, Eric A. Wilson, Pauline Hamon, Clotilde Hennequin, Miriam Saffern, \u2026Diego Chowell Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. 2025."},{"issue":"3","key":"10.1016\/j.biopha.2025.118669_bib166","article-title":"657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma","volume":"8","author":"Chantal","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"16_ement","key":"10.1016\/j.biopha.2025.118669_bib167","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1158\/1538-7445.AM2020-5390","article-title":"High serum interleukin 6 level associates with early death after initiation of treatment with PD-1 inhibitor in advanced NSCLC","volume":"80","author":"Oya","year":"2020","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118669_bib168","doi-asserted-by":"crossref","first-page":"374","DOI":"10.17340\/jkna.2024.0009","article-title":"Atezolizumab induced optic neuritis and aseptic meningitis","volume":"42","author":"Jeong","year":"2024","journal-title":"J. Korean Neurol. Assoc."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:36:14Z","timestamp":1775781374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":168,"alternative-id":["S0753332225008637"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118669","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurologic complications of immune checkpoint inhibitors: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118669"}}